These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30778331)

  • 1. Polychromatic Light Exposure as a Therapeutic in the Treatment and Management of Parkinson's Disease: A Controlled Exploratory Trial.
    Willis GL; Boda J; Freelance CB
    Front Neurol; 2018; 9():741. PubMed ID: 30778331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson's disease.
    Willis GL; Moore C; Armstrong SM
    Rev Neurosci; 2012 Mar; 23(2):199-226. PubMed ID: 22499678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study.
    Willis GL; Turner EJ
    Chronobiol Int; 2007; 24(3):521-37. PubMed ID: 17612949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of bright light therapy on depression and sleep disturbances in patients with Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.
    Lin F; Su Y; Weng Y; Lin X; Weng H; Cai G; Cai G
    Sleep Med; 2021 Jul; 83():280-289. PubMed ID: 34052783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind randomized controlled trial to assess the effect of bright light therapy on depression in patients with Parkinson's disease.
    Rutten S; Vriend C; Smit JH; Berendse HW; Hoogendoorn AW; van den Heuvel OA; van der Werf YD
    BMC Psychiatry; 2016 Oct; 16(1):355. PubMed ID: 27769202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
    Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
    J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process.
    Willis GL
    Rev Neurosci; 2008; 19(4-5):245-316. PubMed ID: 19145986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of light exposure on insomnia and nocturnal movement in Parkinson's disease: an open label, retrospective, longitudinal study.
    Martino JK; Freelance CB; Willis GL
    Sleep Med; 2018 Apr; 44():24-31. PubMed ID: 29530365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nocturnal disturbances and restlessness in Parkinson's disease: using the Japanese version of the Parkinson's disease sleep scale-2.
    Suzuki K; Miyamoto M; Miyamoto T; Tatsumoto M; Watanabe Y; Suzuki S; Iwanami M; Sada T; Kadowaki T; Numao A; Trenkwalder C; Hirata K
    J Neurol Sci; 2012 Jul; 318(1-2):76-81. PubMed ID: 22534309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between the Movement Disorder Society's Unified Parkinson's Disease Rating Scale and Nonmotor Scales in Patients with Parkinson's Disease.
    Driver-Dunckley ED; Zhang N; Shill HA; Mehta SH; Belden CM; Zamrini EY; Davis K; Beach TG; Adler CH
    Innov Clin Neurosci; 2019 Sep; 16(9-10):27-29. PubMed ID: 32082946
    [No Abstract]   [Full Text] [Related]  

  • 14. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
    Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
    Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
    Lhommée E; Wojtecki L; Czernecki V; Witt K; Maier F; Tonder L; Timmermann L; Hälbig TD; Pineau F; Durif F; Witjas T; Pinsker M; Mehdorn M; Sixel-Döring F; Kupsch A; Krüger R; Elben S; Chabardès S; Thobois S; Brefel-Courbon C; Ory-Magne F; Regis JM; Maltête D; Sauvaget A; Rau J; Schnitzler A; Schüpbach M; Schade-Brittinger C; Deuschl G; Houeto JL; Krack P;
    Lancet Neurol; 2018 Mar; 17(3):223-231. PubMed ID: 29452685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical phenotype of drug-naïve Parkinson's disease based on nonmotor symptoms.
    Lee HM; Lee SS; Kim M; Kang SH; Seo WK; Kim JH; Koh SB
    Arch Gerontol Geriatr; 2015; 61(3):517-22. PubMed ID: 26183203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
    Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
    Santos-García D; de la Fuente-Fernández R
    J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Italian version of the Non Motor Symptoms Scale for Parkinson's disease.
    Cova I; Di Battista ME; Vanacore N; Papi CP; Alampi G; Rubino A; Valente M; Meco G; Contri P; Di Pucchio A; Lacorte E; Priori A; Mariani C; Pomati S
    Parkinsonism Relat Disord; 2017 Jan; 34():38-42. PubMed ID: 28029554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson's disease: a multicentre cross-sectional study.
    Suzuki K; Okuma Y; Uchiyama T; Miyamoto M; Sakakibara R; Shimo Y; Hattori N; Kuwabara S; Yamamoto T; Kaji Y; Hirano S; Kadowaki T; Hirata K;
    J Neurol Neurosurg Psychiatry; 2017 Nov; 88(11):953-959. PubMed ID: 28847794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.